Clear Blood — MRD surveillance for blood-based contexts.
CLEAR · MRD SURVEILLANCE FOR BLOOD-BASED CONTEXTS
Clear Blood is molecular residual disease surveillance for blood-based and haematological contexts. After curative-intent treatment, it monitors for the molecular signals of returning disease so that follow-up can be as early and precise as possible.
2 · What it monitors
Disease-specific molecular markers appropriate to the condition, tracked over time from a simple blood draw, with each result read in the context of your baseline and history.
3 · How it works
Baseline → Scheduled monitoring → Interpretation → Clinician review
Baseline
Establish your molecular starting point after treatment.
Scheduled monitoring
Planned blood draws on a subscription cadence.
Interpretation
Each result is read in context by the OnKommon engine.
Clinician review
A changing signal triggers KPCIRC review and a plan.
4 · Honest limits
We believe in transparency about what a test can and cannot do.
MRD surveillance improves the chance of catching a return early, but no test detects every recurrence, and a negative result is reassuring rather than absolute. Clear Blood complements, and does not replace, your scheduled clinical follow-up.
TERMINOLOGY ON THIS PAGE
The words you will see, in plain language
Clear Blood is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A “not detected” or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →